NFKB1 and neoplasm: Importantly, recent studies have shown that bortezomib activates constitutive NF-κB in endothelial cell carcinoma cells (24) and in primary tumor cells from MM patients (21,25), suggesting that inhibition of NF-κB does not solely account for its antitumor activities.